Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

PubWeight™: 9.39‹?› | Rank: Top 0.1%

🔗 View Article (PMID 22281684)

Published in Nature on January 26, 2012

Authors

Anirudh Prahallad1, Chong Sun, Sidong Huang, Federica Di Nicolantonio, Ramon Salazar, Davide Zecchin, Roderick L Beijersbergen, Alberto Bardelli, René Bernards

Author Affiliations

1: Division of Molecular Carcinogenesis, Center for Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

Articles citing this

(truncated to the top 100)

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39

The causes and consequences of genetic heterogeneity in cancer evolution. Nature (2013) 5.91

Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature (2014) 5.19

PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov (2014) 4.81

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med (2015) 4.78

Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer (2013) 4.02

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature (2014) 3.80

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell (2012) 3.37

The next-generation sequencing revolution and its impact on genomics. Cell (2013) 3.35

The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med (2013) 3.20

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun (2014) 3.12

Tumor adaptation and resistance to RAF inhibitors. Nat Med (2013) 3.11

Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol (2012) 3.10

Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 3.09

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature (2014) 2.84

Individualized medicine from prewomb to tomb. Cell (2014) 2.76

Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov (2013) 2.65

Melanoma: from mutations to medicine. Genes Dev (2012) 2.59

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov (2012) 2.56

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet (2015) 2.46

ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell (2014) 2.44

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol (2015) 2.33

An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell (2013) 2.30

Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med (2016) 2.15

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest (2013) 2.11

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol (2015) 2.00

Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov (2012) 1.97

Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci Signal (2013) 1.96

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res (2012) 1.92

Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol (2013) 1.77

Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol (2012) 1.72

Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. Nat Biotechnol (2017) 1.72

Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer (2014) 1.71

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discov (2015) 1.70

A combinatorial strategy for treating KRAS-mutant lung cancer. Nature (2016) 1.69

How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn (2012) 1.66

Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. Mol Cancer Res (2014) 1.65

Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer (2013) 1.61

Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther (2012) 1.60

Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. Cancer Discov (2015) 1.59

MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell (2014) 1.59

Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology (2014) 1.57

Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells. Elife (2015) 1.46

Clinical analysis and interpretation of cancer genome data. J Clin Oncol (2013) 1.44

Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs. PLoS One (2015) 1.43

Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41

ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene (2013) 1.40

Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics (2012) 1.39

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer (2017) 1.39

BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment. Invest New Drugs (2015) 1.37

A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell (2013) 1.35

The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One (2012) 1.34

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discov (2015) 1.28

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer (2015) 1.28

Stable RNA interference rules for silencing. Nat Cell Biol (2014) 1.26

Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer. Proc Natl Acad Sci U S A (2012) 1.25

The MAPK pathway across different malignancies: a new perspective. Cancer (2014) 1.22

MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol (2014) 1.22

Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. Clin Cancer Res (2013) 1.21

Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy. Cancer Cell (2015) 1.21

DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer. Genome Biol (2012) 1.21

mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov (2013) 1.21

A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci U S A (2012) 1.21

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer (2012) 1.18

Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol Cancer Ther (2014) 1.18

Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial. Front Genet (2014) 1.17

The combinatorial complexity of cancer precision medicine. Oncoscience (2014) 1.16

Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer (2015) 1.15

Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc Natl Acad Sci U S A (2014) 1.15

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLoS One (2015) 1.15

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer (2014) 1.14

Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia (2012) 1.14

What are we learning from the cancer genome? Nat Rev Clin Oncol (2012) 1.13

Cancer heterogeneity--a multifaceted view. EMBO Rep (2013) 1.11

Approach to the patient with anaplastic thyroid carcinoma. J Clin Endocrinol Metab (2012) 1.11

Targeting SREBP-1-driven lipid metabolism to treat cancer. Curr Pharm Des (2014) 1.11

Molecular dissection of microsatellite instable colorectal cancer. Cancer Discov (2013) 1.10

The dynamic control of signal transduction networks in cancer cells. Nat Rev Cancer (2015) 1.09

Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies. J Cancer Res Clin Oncol (2013) 1.08

De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov (2013) 1.07

Network quantification of EGFR signaling unveils potential for targeted combination therapy. Mol Syst Biol (2013) 1.07

Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep (2015) 1.07

Adaptive stress signaling in targeted cancer therapy resistance. Oncogene (2015) 1.07

BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment? Curr Treat Options Oncol (2017) 1.06

Ten things you should know about protein kinases: IUPHAR Review 14. Br J Pharmacol (2015) 1.06

Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Clin Cancer Res (2014) 1.05

Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer. Front Oncol (2012) 1.05

PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res (2013) 1.04

MEK genomics in development and disease. Brief Funct Genomics (2012) 1.04

Opposing activities of the Ras and Hippo pathways converge on regulation of YAP protein turnover. EMBO J (2014) 1.04

Rule-based modeling: a computational approach for studying biomolecular site dynamics in cell signaling systems. Wiley Interdiscip Rev Syst Biol Med (2013) 1.04

Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biol Ther (2013) 1.03

The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias. Nat Genet (2015) 1.03

RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth. Nat Cell Biol (2015) 1.03

Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF. Front Oncol (2013) 1.02

Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev (2013) 1.02

Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Oncotarget (2015) 1.02

Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin Cancer Res (2014) 1.01

Markers of resistance to anti-EGFR therapy in colorectal cancer. J Gastrointest Oncol (2013) 1.01

Articles cited by this

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

The protein kinase complement of the human genome. Science (2002) 35.36

K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73

Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol (1995) 9.03

The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer (2005) 8.99

High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res (2003) 8.67

BRAF mutations in hairy-cell leukemia. N Engl J Med (2011) 7.05

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol (2009) 7.04

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol (2009) 4.94

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab (2003) 4.93

BRAF mutation in metastatic colorectal cancer. N Engl J Med (2009) 3.68

ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell (2009) 2.93

An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol (2006) 2.91

BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol (2004) 2.21

Transient poly(ADP-ribosyl)ation of nuclear proteins and role of poly(ADP-ribose) polymerase in the early stages of apoptosis. J Biol Chem (1998) 2.04

Regulation of Cdc25C by ERK-MAP kinases during the G2/M transition. Cell (2007) 1.97

Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase. J Biol Chem (2002) 1.37

EGFR in melanoma: clinical significance and potential therapeutic target. J Cutan Pathol (2011) 1.32

Articles by these authors

Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36

A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15

A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 35.21

High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94

International network of cancer genome projects. Nature (2010) 20.35

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21

A genomic and functional inventory of deubiquitinating enzymes. Cell (2005) 9.36

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77

A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 8.67

Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA (2010) 8.21

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12

Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell (2002) 7.88

IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat (2009) 7.68

Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 7.65

Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol (2005) 7.43

Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature (2003) 6.53

Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res (2007) 5.54

Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009) 4.82

Statistical methods for analysis of high-throughput RNA interference screens. Nat Methods (2009) 4.76

Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76

Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat Cell Biol (2006) 4.67

Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science (2004) 4.67

Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics (2006) 4.57

Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol (2006) 4.54

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst (2009) 4.42

The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell (2005) 4.40

The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol (2005) 4.29

Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature (2008) 4.24

MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell (2012) 4.01

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov (2011) 3.86

Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta (2008) 3.74

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res (2008) 3.70

A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell (2005) 3.35

Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A (2004) 3.35

Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol (2013) 3.34

Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 3.23

Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest (2010) 3.11

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol (2012) 3.02

ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology (2012) 3.00

Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology (2007) 2.95

ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell (2009) 2.93

An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol (2006) 2.91

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov (2013) 2.87

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79

The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell (2005) 2.73

Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res (2013) 2.61

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res (2011) 2.27

Global gene disruption in human cells to assign genes to phenotypes by deep sequencing. Nat Biotechnol (2011) 2.23

Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature (2007) 2.19

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One (2009) 2.18

Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J Biol Chem (2003) 2.14

Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol (2012) 2.07

ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology (2012) 1.99

Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res (2007) 1.98

p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther (2004) 1.90

ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology (2012) 1.86

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut (2012) 1.84

NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell (2010) 1.81

Expression profiling predicts outcome in breast cancer. Breast Cancer Res (2002) 1.81

The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol (2010) 1.80

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med (2014) 1.79

Identifying tumor origin using a gene expression-based classification map. Cancer Res (2003) 1.78

The translation initiation factor 3f (eIF3f) exhibits a deubiquitinase activity regulating Notch activation. PLoS Biol (2010) 1.77

ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology (2012) 1.68

Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res (2004) 1.68

shRNA libraries and their use in cancer genetics. Nat Methods (2006) 1.66

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci U S A (2008) 1.66

A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling. Genes Dev (2002) 1.65

Mutational profile of GNAQQ209 in human tumors. PLoS One (2009) 1.62

Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer (2013) 1.60